Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 255

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

Reddy, K. Rajender, Bourlière, Marc, Sulkowski, Mark, Omata, Masao, Zeuzem, Stefan, Feld, Jordan J., Lawitz, Eric, Marcellin, Patrick, Welzel, Tania M., Hyland, Robert, Ding, Xiao, Yang, Jenny, Knox, Steven, Pang, Phillip, Dvory‐Sobol, Hadas, Subramanian, G. Mani, Symonds, William, McHutchison, John G., Mangia, Alessandra, Gane, Edward, Mizokami, Masashi, Pol, Stanislas, Afdhal, Nezam · 2015 · Hepatology

Abstract

Patients with hepatitis C virus (HCV) infection and cirrhosis are underrepresented in clinical trials of interferon‐free regimens of direct‐acting antiviral agents, making it difficult to optimize therapy. We performed a post‐hoc analysis of data from seven clinical trials to evaluate the efficacy and safety of the fixed‐dose combination of ledipasvir (LDV) and sofosbuvir (SOF), with and without ribavirin (RBV), in 513 treatment‐naïve and previously treated patients with genotype 1 HCV and compensated cirrhosis. All patients received LDV‐SOF for 12 or 24 weeks with or without RBV. We determined the rates of sustained virological response (SVR) 12 weeks after treatment (SVR12) overall and for subgroups. Of the 513 patients analyzed, 69% were previously treated and 47% had failed previous treatment with a protease‐inhibitor regimen. Overall, 493 patients (96%; 95% confidence interval [CI]: 94%‐98%) achieved SVR12, 98% of treatment‐naïve and 95% of previously treated patients. SVR12 rates did not vary greatly by treatment duration (95% of patients receiving 12 weeks and 98% of patients receiving 24 weeks of treatment), nor by addition of RBV (95% of patients receiving LDV‐SOF alone and 97% of those who received LDV‐SOF plus RBV), although previously treated patients receiving 12 weeks of LDV‐SOF without RBV had an SVR12 rate of 90%. One patient discontinued LDV‐SOF because of an adverse event (AE). The most common AEs were headache (23%), fatigue (16%‐19%), and asthenia (14%‐16%). One patient (<1%) of those receiving LDV‐SOF alone, and 4 (2%) of those receiving LDV‐SOF plus RBV had treatment‐related serious AEs. Conclusions: This analysis suggests that 12 weeks of LDV‐SOF is safe and effective for treatment‐naïve patients with HCV genotype 1 and compensated cirrhosis. The relatively lower SVR in treatment‐experienced patients treated with 12 weeks of LDV‐SOF raises the question of whether these patients would benefit from adding RBV or extending treatment duration to 24 weeks. (H epatology 2015;62:79‐86)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.27826

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 255

Metadata

Authors
Reddy, K. R., Bourlière, M., Sulkowski, M., Omata, M., Zeuzem, S., Feld, J. J., Lawitz, E., Marcellin, P., Welzel, T. M., Hyland, R., Ding, X., Yang, J., Knox, S., Pang, P., Dvory‐Sobol, H., Subramanian, G. M., Symonds, W., McHutchison, J. G., Mangia, A., Gane, E., Mizokami, M., Pol, S., & Afdhal, N.
Venue
Hepatology
Published
2015-05-09
Volume
62
Issue
1
Pages
79-86
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W1732930179
Cited by
255
References
11
FWCI
32.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. https://app.cochat.ai/papers/10.1002/hep.27826
The paper
Reddy, K. R., Bourlière, M., Sulkowski, M., Omata, M., Zeuzem, S., Feld, J. J., Lawitz, E., Marcellin, P., Welzel, T. M., Hyland, R., Ding, X., Yang, J., Knox, S., Pang, P., Dvory‐Sobol, H., Subramanian, G. M., Symonds, W., McHutchison, J. G., Mangia, A., . . . Afdhal, N. (2015). Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. https://doi.org/10.1002/hep.27826

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.